Publications by authors named "Luanna Tardio"
Article Synopsis
- mTOR is a key player in the PI3K/AKT signaling pathway, which is disrupted in 50% of human cancers, and while rapamycin inhibits mTORC1, it doesn't target mTORC2, which is also important for cancer progression.
- WYE-125132 (WYE-132) is a highly effective ATP-competitive inhibitor that targets both mTORC1 and mTORC2, leading to reduced AKT activity without diminishing other key signaling pathways.
- In preclinical studies, WYE-132 demonstrated significant anti-tumor effects in various cancer models, outperforming existing treatments like temsirolimus, suggesting its potential as a novel cancer therapy.
In vitro and in vivo activities of novel 6-methylidene penems as beta-lactamase inhibitors.
Antimicrob Agents Chemother
December 2004
Novel penem molecules with heterocycle substitutions at the 6 position via a methylidene linkage were investigated for their activities and efficacy as beta-lactamase inhibitors. The concentrations of these molecules that resulted in 50% inhibition of enzyme activity were 0.4 to 3.
View Article and Find Full Text PDFObjective: The role that the surface proteins anchored by the srtA and srtB gene products play in the ability of Staphylococcus aureus bacteria to establish infection was investigated in several animal models.
Methods: Wild-type and corresponding mutants with deletions of the srtA and/or srtB genes were used in murine acute lethal infection, septic arthritis, kidney infection and rat endocarditis models.
Results: The LD(50) of the wild-type and srtB- knockout were comparable and approximately two- to four-fold lower than the required inoculum of the srtA- and srtA-B- strains.